Results 221 to 230 of about 264,442 (390)

The role of body composition in left ventricular remodeling, reverse remodeling, and clinical outcomes for heart failure with mildly reduced ejection fraction: more knowledge to the “obesity paradox” [PDF]

Kang Fu, Youran Dong, Zhiyuan Wang, Junlin Teng, Congyi Cheng, Cong Su, Xiaoping Ji, Huixia Lu   +7 more
openalex   +1 more source

Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.

Journal of the American College of Cardiology, 2018
S. Greene, J. Butler, N. Albert, A. DeVore, Puza P. Sharma, Carol I. Duffy, C. L. Hill, K. Mccague, Xiaojuan Mi, J. Patterson, J. Spertus, L. Thomas, Fredonia B. Williams, Adrian F. Hernandez, G. Fonarow   +14 more
semanticscholar   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Low-Dose Vericiguat in Heart Failure With Reduced Ejection Fraction: A Case Report. [PDF]

Cureus
Orji C.
europepmc   +1 more source

Spironolactone Reduces the Risk of Death in Veterans With Heart Failure With Preserved Ejection Fraction

Katherine E. Kurgansky, Rachel Parker, Luc Djoussé, David Gagnon, Jacob Joseph   +4 more
openalex   +1 more source

Evaluation of Sleep Quality with Use of Angiotensin Receptor Neprilysin Inhibitor in Patients with Reduced Ejection Fraction Heart Failure

, 2022
Ferhat Işık, Metin Okşul, Burhan Aslan, Ercan Taştan   +3 more
openalex   +2 more sources

N‐of‐1 trials in clinical research: Methodological foundations, statistical approaches and implementation challenges

British Journal of Clinical Pharmacology, EarlyView.
N‐of‐1 trials offer a unique and rigorous methodology for evaluating individualized treatment responses, particularly within the context of personalized medicine. This article provides a comprehensive explanation of the conceptual and methodological underpinnings of N‐of‐1 trials, with particular emphasis on statistical techniques and considerations ...
Marcos Clint Leal De Carvalho, Matheus de Matos Dourado Simões, Ubiratan Cardinalli Adler, Antonio Brazil Viana Junior, Caren Nádia Soares de Sousa, Lia Lira Olivier Sanders   +5 more
wiley   +1 more source

Withdrawal: “Socioeconomic status and prognosis of heart failure with reduced vs. preserved ejection fraction: A propensity‐matched study in the community” [PDF]

, 2020

openalex   +1 more source

An open‐label, single‐arm, dose‐escalating concentration–QT study to investigate the cardiac effects and safety of paroxetine in healthy adults

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Paroxetine is a selective serotonin reuptake inhibitor (SSRI), approved for treatment of major depressive disorder and anxiety disorders. Some SSRIs are known to prolong the QT interval; however, clinical evidence to establish a lack of association between paroxetine and corrected QT interval (QTc) prolongation is limited. Therefore, this
Sven C. van Dijkman, Mathieu Félices, Bhaskar Pandurangavittal, Sanman Ghorpade, Caroline Easterbrook, Marcin Zabielski, Oscar Della Pasqua   +6 more
wiley   +1 more source

Vericiguat Therapy Is Associated with Reverse Myocardial Remodeling in Chronic Heart Failure with Reduced Ejection Fraction. [PDF]

J Cardiovasc Dev Dis
Bajec T, Žorž N, Ugovšek S, Zemljič G, Cerar A, Frljak S, Okrajšek R, Girandon Sušanj P, Šebeštjen M, Vrtovec B, Poglajen G.   +10 more
europepmc   +1 more source